About: Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2000 (uk) im September 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 2000 (ast) scientific article published on 01 September 2000 (en)
publication date	wds:Q73101615-35C55055-F6C1-49CB-8D9F-049D42A49353
publication date	2000-09-01 00:00:00Z (xsd:dateTime)
exact match	wds:Q73101615-6BA2A544-1E66-4D3C-9C8B-B7ED0B9A8B1D
exact match	https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702590
cites work	wds:Q73101615-12872879-A811-4F9A-96F4-2D11F2C0798B wds:Q73101615-24C7AFD0-2A10-4340-8356-A903C1434DEC wds:Q73101615-29C203FF-28E9-4C33-B905-04AD92273CE3 wds:Q73101615-36FAD146-DC40-4458-A8DA-8CAED7CA8808 wds:Q73101615-4EBE98EC-1B44-4638-8E30-11ECCC192749 wds:Q73101615-5AC60AC8-F864-4B14-9A26-0B2A1E25645F wds:Q73101615-7750BE13-7107-4E8D-9F86-909D3F5EA500 wds:Q73101615-84BFEBF5-3A70-4CD9-8FFD-1F6F686CC614 wds:Q73101615-947B0FBB-1531-4BC3-93A5-25E6EB418DE3 wds:Q73101615-9EC523F2-6842-45EC-B85B-6442FE391E31 wds:Q73101615-A0B6F90A-98DA-4F4A-BCED-51754DF1EAC1 wds:Q73101615-B0476E8F-1B25-48F6-AE34-E0C1EA42A8C9 wds:Q73101615-B9943522-A74A-44F8-A4B3-06071D989F94 wds:Q73101615-BA25E86B-E1BC-4599-81C0-433975759729 wds:Q73101615-C2918829-84A2-476B-B473-7B0A2AEA74A5 wds:Q73101615-D8A52CC3-662F-4632-AF26-8D5A9B766050 wds:Q73101615-DE198254-E58A-41F9-80F3-6166B9FF9E54 wds:Q73101615-E8294785-BB9E-4520-BE6F-D3555AFD0545 wds:Q73101615-EC10D325-41EF-4B0A-87BE-C38B759565CF wds:Q73101615-ED6DB3CD-82B0-4D3C-81F5-1D319EE68F5E
cites work	Nonparametric Estimation from Incomplete Observations Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide Busulfan. Aspects concerning busulfan pharmacokinetics and bioavailability Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Marrow transplantation for thalassaemia following busulphan and cyclophosphamide High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Pharmacokinetics of high-dose busulfan in children Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moe Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation Graft-Versus-Host Disease: Pathophysiological and Clinical Aspects Growth in children undergoing bone marrow transplantation after busulfan and cyclophosphamide conditioning. Growth after bone marrow transplantation in young children conditioned with chemotherapy alone
author name string	wds:Q73101615-014FB3F8-2E35-4E72-9EAD-829190856AEC wds:Q73101615-10579285-C421-45B1-A40C-E435B7C05692 wds:Q73101615-1D2965CC-184B-4789-A3B3-96AC0B3FD759 wds:Q73101615-3DCBB0BA-CDE8-4ADA-A971-782BDF45998A wds:Q73101615-89F14E80-18D4-48F6-80B2-706BC487B612
author name string	DeFor T Ramsay NK Woods WG Baker KS Bostrom B
rdfs:label	Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (en) Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (nl)
skos:prefLabel	Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (en) Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (nl)
name	Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (en) Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (nl)
author	wds:Q73101615-A98C883F-AA1B-42EA-B82D-C8A49C9969B2
author	Bruce R Blazar
title	wds:Q73101615-284827EC-7030-4989-BEA6-F5C42B693D27
title	Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia (en)
page(s)	wds:Q73101615-109846F7-913A-4296-BE8F-5BE94C3C5D90
page(s)	607-614
instance of	wds:Q73101615-E452AF83-BBAD-4C8A-B035-D4575738BB33
instance of	scholarly article
main subject	wds:Q73101615-8E018295-2825-4FF1-BE1F-1C620931D41C wds:Q73101615-C2236637-433F-4934-B26F-68511B524AEB
main subject	acute myeloid leukemia pharmacokinetics
PubMed ID	wds:Q73101615-C8BAA7EC-BA45-48FB-9C15-1480E071DFAC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11041565
PubMed ID	11041565
published in	wds:Q73101615-389A3739-9B4D-4190-BE66-9FA29CA74B7F
published in	Bone Marrow Transplantation
issue	wds:Q73101615-56591DC4-E6B4-448F-82B7-6A323CC43EB6
volume	wds:Q73101615-551AFA2F-EF24-43AE-BB90-62E687F2E59D
issue	6
volume	26
DOI	wds:Q73101615-0B806B07-2BE8-4D2E-BB79-5C67C38896D2
DOI	http://dx.doi.org/10.1038/SJ.BMT.1702590
DOI	10.1038/SJ.BMT.1702590
Dimensions Publication ID	wds:Q73101615-0021D074-C47D-4CBF-B288-D1094F554AF3
Dimensions Publication ID	1007638510
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73101615
is cites work of	Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software